The device, currently used to plug the patent foramen ovale-type of hole in the heart, is now being trialled as a treatment for migraine.
The US-based medical devices manufacturer has charged Ash with promoting the device across the Continent via a campaign targeting doctors.
The campaign will report on the progress of the Migraine Intervention with StarFlex Technology (Mist) trial, which runs throughout the first three quarters of this year.
NMT has retained Ash for pan-European work following its media relations campaign to promote enrolment for the trial in January, having first hired the agency on a project basis last year.
The agency will also develop a campaign for the next generation of the device, called Biostar, for which trials are scheduled to begin in the second quarter of this year.
The account is led by Ash director Carys Thomas Ampofo.